Beam Therapeutics Inc - Asset Resilience Ratio
Beam Therapeutics Inc (BEAM) has an Asset Resilience Ratio of 62.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check BEAM capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Beam Therapeutics Inc's Asset Resilience Ratio has changed over time. See BEAM equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Beam Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Beam Therapeutics Inc (BEAM) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $923.36 Million | 62.36% |
| Total Liquid Assets | $923.36 Million | 62.36% |
Asset Resilience Insights
- Very High Liquidity: Beam Therapeutics Inc maintains exceptional liquid asset reserves at 62.36% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Beam Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Beam Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Beam Therapeutics Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Beam Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.16% | $950.27 Million | $1.48 Billion | +12.63pp |
| 2024-12-31 | 51.53% | $568.77 Million | $1.10 Billion | -0.13pp |
| 2023-12-31 | 51.65% | $753.98 Million | $1.46 Billion | -11.35pp |
| 2022-12-31 | 63.01% | $845.37 Million | $1.34 Billion | +35.49pp |
| 2021-12-31 | 27.51% | $405.65 Million | $1.47 Billion | -2.93pp |
| 2020-12-31 | 30.44% | $137.50 Million | $451.68 Million | -4.55pp |
| 2019-12-31 | 35.00% | $54.63 Million | $156.10 Million | -- |
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more